

SCIENTIFIC REPORTS



OPEN

Functional differences between AMPK α 1 and α 2 subunits in osteogenesis, osteoblast-associated induction of osteoclastogenesis, and adipogenesis

Received: 04 February 2016
Accepted: 15 August 2016
Published: 07 September 2016

Yu-gang Wang, Xiu-guo Han, Ying Yang, Han Qiao, Ke-rong Dai, Qi-ming Fan & Ting-ting Tang

The endocrine role of the skeleton—which is impaired in human diseases including osteoporosis, obesity and diabetes—has been highlighted previously. In these diseases, the role of AMPK, a sensor and regulator of energy metabolism, is of biological and clinical importance. Since AMPK's main catalytic subunit α has two isoforms, it is unclear whether functional differences between them exist in the skeletal system. The current study overexpressed AMPK α 1 and α 2 in MC3T3-E1 cells, primary osteoblasts and mouse BMSCs by lentiviral transduction. Cells overexpressing AMPK α 2 showed higher osteogenesis potential than AMPK α 1, wherein androgen receptor (AR) and osteoactivin played important roles. RANKL and M-CSF were secreted at lower levels from cells overexpressing α 2 than α 1, resulting in decreased osteoblast-associated osteoclastogenesis. Adipogenesis was inhibited to a greater degree in 3T3-L1 cells overexpressing α 2 than α 1, which was modulated by AR. An abnormal downregulation of AMPK α 2 was observed in human BMSCs exhibiting the fibrous dysplasia (FD) phenotype. Overexpression of AMPK α 2 in these cells rescued the defect in osteogenesis, suggesting that AMPK α 2 plays a role in FD pathogenesis. These findings highlight functional differences between AMPK α 1 and α 2, and provide a basis for investigating the molecular mechanisms of diseases associated with impaired functioning of the skeletal system.

Several important hormones secreted by bone cells regulate energy balance and mineral ion homeostasis. This endocrine function of the skeleton is impaired in various diseases including osteoporosis, obesity, and diabetes-associated bone diseases¹. Elucidating the molecular basis for the regulation of energy metabolism and hormone production in the skeleton is therefore of biological and clinical importance, and can provide insight into the pathogenesis of these diseases.

Adenosine triphosphate (ATP) is an immediate source of energy in living cells and must therefore be maintained at a relatively high level. In eukaryotic cells, the adenosine monophosphate (AMP)-activated protein kinase (AMPK) signaling cascade detects and initiates a response to decreases in cellular ATP concentration² by coupling changes in the intracellular level of ATP to the phosphorylation of downstream substrates, resulting in increases or decreases in the rates of ATP production and consumption, respectively³.

Bone is a dynamic organ that is continuously remodeled throughout the lifetime of an organism and is susceptible to alterations in metabolic status and physiological state. Recent studies have revealed that bone metabolism is regulated by the brain and is closely linked to whole body energy homeostasis^{1,4,5}. There are two main neuronal populations within the arcuate nucleus of the hypothalamus regulating energy homeostasis: The orexigenic,

Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, 639 Zhizaoju Road, Shanghai 200011, People's Republic of China. Correspondence and requests for materials should be addressed to Q.-m.F. (email: chillow@163.com) or T.-t.T. (email: tingtingtang@hotmail.com)

appetite-stimulating neurons and the anorexigenic, appetite-suppressing neurons. They encompass some of the most effective control of energy homeostasis in the entire body. In addition, they also are involved in regulating of skeletal homeostasis and linking the processes of bone and energy homeostasis. Remarkably, the number of central neuropeptides and neural factors regulating bone and energy homeostasis keeps growing. These neuronal pathways represent a growing area with intensive research interest that is looking for novel regulatory axes between the brain and the bone. As a sensor of energy metabolisms, the *in vitro* and *in vivo* evidence for AMPK regulation of osteoblast differentiation is controversial^{6–8}, and the precise role of AMPK in bone metabolism remains an open question.

Mammalian AMPK comprises α , β , and γ subunits in a heterotrimeric complex^{9,10}. The α subunit has two isoforms, $\alpha 1$ and $\alpha 2$, and contains a kinase domain at the N terminus, which is phosphorylated at Thr172 by upstream kinases¹¹. The $\alpha 1$ subunit is widely expressed, whereas the $\alpha 2$ subunit is highly expressed in skeletal and cardiac muscle and in the liver¹²; a recent study showed that AMPK activation by electrical stimulation of rat hindlimb muscle involved the $\alpha 2$ isoform¹³. However, it is unclear whether the $\alpha 1$ and $\alpha 2$ isoforms have distinct biological functions in the skeletal system.

The present study investigated whether functional differences exist between AMPK $\alpha 1$ and $\alpha 2$ subunits with respect to osteogenesis, osteoblast-associated induction of osteoclastogenesis, and adipogenesis. The results indicated that the subunit composition of AMPK determines the susceptibility of MC3T3-E1, 3T3-L1, primary osteoblasts and bone marrow stromal cells (BMSCs) to osteogenic, osteoclastogenic, and adipogenic induction, which involved androgen receptor (AR), osteoactivin, macrophage colony-stimulating factor (M-CSF), and receptor activator of nuclear factor κ B ligand (RANKL). Interestingly, an aberrant downregulation of the $\alpha 2$ subunit was associated with the fibrous dysplasia (FD) phenotype in BMSCs characterized by impaired osteogenesis, which was rescued by overexpressing the $\alpha 2$ subunit. These findings highlight functional differences between AMPK $\alpha 1$ and $\alpha 2$, and provide a basis for investigating the molecular mechanisms of diseases associated with impaired functioning of the skeletal system.

Results

AMPK $\alpha 1$ and $\alpha 2$ mRNA expression is upregulated during osteogenesis. MC3T3-E1 cells used in the current study are preosteoblasts derived from mouse calvaria and have been used extensively as an *in vitro* model system to examine the osteogenic differentiation. On days 0, 2, 4, and 7 after induction, the expression of Runt-related transcription factor 2/core-binding factor $\alpha 1$ (*Runx2*), alkaline phosphatase (*Alp*), *Phospho1*, osteocalcin (*Ocn*), and *Ampk* $\alpha 1$ and $\alpha 2$ subunits was examined by qRT-PCR. An increase in the transcript levels of *Runx2* (Fig. 1A), *Alp* (Fig. 1B), and *Phospho1* (Fig. 1C) between days 2 and 7 and *Ocn* (Fig. 1D) on day 7 relative to day 0 was observed, indicating that MC3T3-E1 cells differentiated into osteoblasts. *Ampk* $\alpha 1$ (Fig. 1E) and $\alpha 2$ (Fig. 1F) mRNA expression was also upregulated on days 4 and 7 after induction.

Primary calvarial osteoblasts were induced to osteogenesis. On days 0, 3, 9, and 15 after induction, the expression of *Osterix*, *Alp*, *Ibsp*, *Ocn*, and *Ampk* $\alpha 1$ and $\alpha 2$ subunits was examined by qRT-PCR. An increase in the transcript levels of *Osterix* (Fig. 1G), *Alp* (Fig. 1H), *Ocn* (Fig. 1I) between days 9 and 15 and *Ibsp* (Fig. 1I) between days 3 and 15 relative to day 0 was observed. *Ampk* $\alpha 1$ (Fig. 1K) and $\alpha 2$ (Fig. 1L) mRNA expression was also upregulated between days 3 and 15 compared with day 0.

Also, BMSCs were induced to osteogenesis. On weeks 0, 1, 2, and 3 after induction, the expression of *Runx2*, *Alp*, *Phospho1*, *Ocn*, and *Ampk* $\alpha 1$ and $\alpha 2$ subunits was examined by qRT-PCR. As an early-stage marker gene of osteogenic differentiation and one of the most important transcriptional factors to initiate osteogenesis, *Runx2* mRNA levels showed a biphasic response during osteogenic differentiation, that is, increased from weeks 0 to 1 and reached its maximal levels at weeks 1 and thereupon fell progressively till weeks 3. Of these, there were statistically higher mRNA levels from weeks 1 to 3, relative to weeks 0 (Fig. 1M). An increase in the transcript levels of *Alp* (Fig. 1N) between weeks 1 and 3 and *Phospho1* (Fig. 1O) and *Ocn* (Fig. 1P) between weeks 2 and 3 relative to day 0 was observed, indicating that BMSCs differentiated into osteoblasts. *Ampk* $\alpha 1$ (Fig. 1Q) and $\alpha 2$ (Fig. 1R) mRNA expression was also upregulated between weeks 1 and 3 compared with week 0.

Osteogenic potential is enhanced in cells overexpressing AMPK $\alpha 2$ compared with AMPK $\alpha 1$.

To investigate whether there are functional differences between AMPK $\alpha 1$ and $\alpha 2$ subunits, exogenous AMPK $\alpha 1$ and $\alpha 2$ subunits were constitutively expressed in MC3T3-E1, primary osteoblasts and mouse BMSCs. The AMPK $\alpha 1$ and $\alpha 2$ subunit coding sequences were cloned into lentivirus (LV) vectors that were transduced into MC3T3-E1, primary osteoblasts and BMSCs (Fig. 2A), with the empty LV vector serving as a control. In MC3T3-E1, primary osteoblasts and BMSCs, exogenous AMPK $\alpha 1$ and $\alpha 2$ subunits were overexpressed in LV-AMPK $\alpha 1$ (Fig. 2B,D,F) and LV-AMPK $\alpha 2$ (Fig. 2C,E,G) clones respectively, as determined by RT-PCR. Moreover, the overexpression of exogenous AMPK $\alpha 1$ and $\alpha 2$ had no effect on the levels of the endogenous AMPK $\alpha 1$ and $\alpha 2$ (Fig. 2B–G).

The AMPK $\alpha 1$ - and $\alpha 2$ -expressing MC3T3-E1 cells were induced to osteogenesis. On day 7 after induction, the expression of the osteogenesis markers *Runx2*, *Alp*, *Bsp*, and *Ocn* was assessed by qRT-PCR. Compared with LV-ctr, the $\alpha 1$ - and $\alpha 2$ -expressing cells had a significant upregulation in *Runx2*, *Alp*, *Ibsp* and *Ocn* (Fig. 3A–D). More importantly, a significant upregulation in *Runx2*, *Alp*, *Ibsp*, and *Ocn* transcript levels was detected in LV-AMPK $\alpha 2$ relative to LV-AMPK $\alpha 1$ cells (Fig. 3A–D). Consistent with these results, when the AMPK agonist AICAR was added in combination with BMP2, mineralization evaluated by Alizarin Red staining (Fig. 3E) and quantification (Fig. 3F) was greater in LV-AMPK $\alpha 2$ than in LV-AMPK $\alpha 1$ cells on days 9 and 12.

Primary osteoblasts overexpressing AMPK $\alpha 1$ or $\alpha 2$ subunits were induced to osteogenesis. On day 9 after induction, the $\alpha 1$ - and $\alpha 2$ -expressing primary osteoblasts had a significant upregulation in *Osterix*, *Alp*, *Ibsp* and *Ocn* (Fig. 3G–J) compared with LV-ctr. A significant upregulation in *Osterix*, *Alp*, *Ibsp* and *Ocn* transcript levels was detected in LV-AMPK $\alpha 2$ relative to LV-AMPK $\alpha 1$ cells (Fig. 3G–J). Consistent with these results, the Alizarin




Figure 1. mRNA expression of AMPK α 1 and α 2 subunits during osteogenesis in MC3T3-E1, primary calvarial osteoblasts and mouse BMSCs. MC3T3-E1, primary osteoblasts and BMSCs were induced to osteogenic differentiation. The expression of *Runx2* (A,M), *Osterix* (G), *Alp* (B,H,N), *Phospho1* (C,O), *Ibsp* (I), *Ocn* (D,J,P), *Ampk α 1* (E,K,Q) and *Ampk α 2* (F,L,R) was evaluated by qRT-PCR. β -actin was used as internal control. The results are expressed as fold changes in mRNA abundance relative to 0d or 0w. Data are shown as mean \pm SD. * $P < 0.05$; ** $P < 0.01$, vs. 0d or 0w.




Figure 2. Generation of MC3T3-E1, primary osteoblasts and mouse BMSCs stably over-expressing AMPK α 1 and α 2 subunits. The AMPK α 1 and α 2 subunit coding sequences were cloned into an LV vector with a CMV promoter and positive clones were selected with puromycin (A). An empty LV vector served as a control (LV-ctr). RT-PCR was employed to check the expression of exogenous and endogenous α 1 (B,D,F) and α 2 (C,E,G) subunits of AMPK was evaluated. β -actin was used as an internal control.

Red staining (Fig. 3K) and quantification (Fig. 3L) results revealed greater mineralization in LV-AMPK α 2 than in LV-AMPK α 1 cells on days 15.

BMSCs overexpressing AMPK α 1 or α 2 subunits were induced to osteogenesis. On day 7 after induction, the α 1- and α 2-expressing BMSCs had a significant upregulation in *Runx2*, *Alp*, and *Ocn* (Fig. 3M–O) compared with LV-ctr. A significant upregulation in *Runx2*, *Alp*, and *Ocn* transcript levels was detected in LV-AMPK α 2 relative to LV-AMPK α 1 cells (Fig. 3M–O). Consistent with these results, the Alizarin Red staining (Fig. 3P) and




Figure 3. Osteogenesis in MC3T3-E1, primary osteoblasts and mouse BMSCs expressing AMPK α 1 and α 2. MC3T3-E1 cells were induced with osteogenic differentiation. On day 7 after induction, the expression of the osteogenesis markers *Runx2* (A), *Alp* (B), *Ibsp* (C), and *Ocn* (D) was evaluated by qRT-PCR. On days 9 and 12 after application of BMP2 and the AMPK agonist AICAR, calcium deposition was assessed by Alizarin Red staining (E) and quantification (F). Primary osteoblasts were induced with osteogenic differentiation. On day 9 after induction, the expression of *Osterix* (G), *Alp* (H), *Ibsp* (I) and *Ocn* (J) was evaluated by qRT-PCR. On days 15 after induction, calcium deposition was assessed by Alizarin Red staining (K) and quantification (L). Mouse BMSCs were induced with osteogenic differentiation. On day 7 after induction, the expression of *Runx2* (M), *Alp* (N), and *Ocn* (O) was evaluated by qRT-PCR. On days 14 after induction, calcium deposition was assessed by Alizarin Red staining (P) and quantification (Q). β -actin was used as an internal control of qRT-PCR. Data are shown as mean \pm SD and are expressed as fold changes in mRNA abundance relative to LV-ctr cultures. * $P < 0.05$, ** $P < 0.01$.

quantification (Fig. 3Q) results revealed greater mineralization in LV-AMPK α 2 than in LV-AMPK α 1 cells on weeks 2.

Further, we examined ectopic bone formation of LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells in nude mice. We implanted β -TCP scaffolds loading with and without MC3T3-E1 cells into the intramuscular pocket of nude mice. Eight weeks after implantation, we harvested the specimens and subjected them to micro-CT imaging and hematoxylin and eosin (H&E) staining. LV-AMPK α MC3T3-E1 cells induced more ectopic bone formation compared to LV-ctr MC3T3-E1 cells (Fig. 4A,B), indicating that AMPK could enhance *in vivo* osteogenesis of MC3T3-E1 cells. Importantly, much more ectopic bone formation was observed in LV-AMPK α 2 MC3T3-E1 cells compared with LV-AMPK α 1 MC3T3-E1 cells (Fig. 4A,B). H&E staining revealed the same pattern as micro-CT (Fig. 4C).

Osteoblast-associated osteoclastogenesis of bone marrow monocytes is attenuated by AMPK α 2 compared with α 1. Osteoclasts differentiation and maturation depends on RANKL and M-CSF secreted by osteoblasts, with the two cell types interacting through direct contact as well as paracrine signaling¹⁴. Here, the capacity for osteoclastogenic induction of MC3T3-E1 cells overexpressing the α 1 or α 2 subunits of AMPK was evaluated. Bone marrow monocytes were co-cultured with LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells in the presence of BMP2, and tartrate-resistant acid phosphatase (TRAP) staining was carried out on day 7. Compared with LV-ctr, LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells had weaker osteoclastogenic induction capacity, as indicated by TRAP staining (Fig. 5A) and evaluation of number (Fig. 5B) and average size (Fig. 5C) of TRAP⁺ osteoclasts. More importantly, the number and average size of TRAP⁺ osteoclasts were 60% lower and 40% smaller, respectively, in monocytes co-cultured with LV-AMPK α 2 as compared to LV-AMPK α 1 MC3T3-E1 cells (Fig. 5A–C).

Further, we investigated the osteoclast function induced by LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells by evaluating resorption pit formation. The results revealed lower osteoclast function induced by LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells compared with LV-ctr cells (Fig. 5D,E). Moreover, lower osteoclast function induced by LV-AMPK α 2 cells was observed compared with LV-AMPK α 1 cells (Fig. 5D,E).




Figure 4. *In vivo* ectopic bone formation in MC3T3-E1 cells over-expressing AMPK α 1 and α 2. β -TCP scaffolds loading with and without MC3T3-E1 cells over-expressing AMPK α 1 and α 2 were implanted into the intramuscular pocket of the femur of nude mice. Eight weeks later, the complexes were harvested and scanned by micro-CT (A). Micro-CT images are shown in apical and lateral views. The measurement of BMD was performed on the basis of micro-CT (B). Then these complexes were decalcified, embedded in paraffin and stained with hematoxylin and eosin (H&E). Data were shown as the mean \pm SD. * $p < 0.05$.

qRT-PCR analysis revealed a downregulation in the expression of osteoclastogenic markers including nuclear factor of activated T cells 2 (*Nfat2*), *Trap*, cathepsin K (*Catk*), calcitonin receptor (*Calcr*), and *integrin* β 3 in bone marrow monocytes co-cultured with LV-AMPK α 1 and LV-AMPK α 2 cells compared with LV-ctr cells (Fig. 5F–J). Moreover, more significant downregulation in the expression of these osteoclastogenic markers was observed in bone marrow monocytes co-cultured with LV-AMPK α 2 cells compared with LV-AMPK α 1 cells (Fig. 5F–J).

Bone metabolism markers expression in MC3T3-E1 cells overexpressing AMPK α 1 and α 2 subunits. Given that overexpressing the α 2 as compared to the α 1 subunit of AMPK conferred a greater osteogenic potential and diminished osteoblast-associated induction of osteoclastogenesis, the potential mechanisms underlying this difference were investigated in cells treated with BMP2 for 7 days by evaluating the protein expression levels of 36 markers of bone metabolism using an antibody array (Fig. 6A). The relative expression level of specific proteins was represented by the fluorescent signal intensity. Among the 36 markers, five markers that were differentially expressed between LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells were of particular interest (Fig. 6A,B). AR and osteoactivin were upregulated by 180% and 110%, respectively, and M-CSF, RANKL, and matrix metalloproteinase (MMP)-24 were downregulated by >90%, 80%, and 70%, respectively, in LV-AMPK α 2 as compared to LV-AMPK α 1 cells (Fig. 6C). There was no significant difference in OPG expression level between LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells, so that higher OPG/RANKL ratio was observed in LV-AMPK α 2 cells as compared to LV-AMPK α 1 cells (Fig. 6C). The expression profiles of the other markers are shown in Supplementary Figure 1. In LV-AMPK α 1 and LV-AMPK α 2 cells treated with BMP2 for 7 days, qRT-PCR analysis revealed an upregulation of *Ar* and *Osteoactivin* and downregulation of *M-csf*, *Rankl*, and *Mmp-24* mRNA levels in LV-AMPK α 2 relative to LV-AMPK α 1 cells (Fig. 6D), consistent with the protein expression data from the antibody array.

Osteoactivin and AR are involved in osteogenesis of AMPK α subunit-overexpressing cells. Osteoactivin and AR play essential roles in osteogenic differentiation^{15–18}. Since the expression of both proteins was higher in MC3T3-E1 cells overexpressing the α 2 compared with the α 1 subunit of AMPK, we investigated whether this was responsible for a greater osteogenic potential in LV-AMPK α 2 as compared to LV-AMPK α 1 cells. To answer this question, LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells were infected, respectively, with LV particles expressing AR and osteoactivin (Fig. 7A) and siRNA against the two proteins (Fig. 7A). The cells were then induced to osteogenesis. A qRT-PCR analysis performed on day 7 showed that the mRNA expression of *Runx2*, *Alp*, *Bsp*, and *Ocn* was upregulated in response to AR and osteoactivin overexpression in LV-AMPK α 1 cells (Fig. 7B–E). In contrast, AR knockdown resulted in the downregulation of *Runx2*, *Alp*, *Ibsp*, and *Ocn* mRNA expression in LV-AMPK α 2 cells (Fig. 7B–E). Osteoactivin knockdown also decreased the mRNA expression of *Runx2*, *Alp*, and *Ocn*, but had no effect on the level of *Ibsp*. On day 21 after induction, Alizarin Red staining and quantification revealed greater mineralization in LV-AMPK α 1 cells overexpressing




Figure 5. Osteoclastogenesis in bone marrow monocytes induced by AMPK α 1- and α 2-expressing MC3T3-E1 cells. Bone marrow monocytes were co-cultured with LV-AMPK α 1 and LV-AMPK α 2 MC3T3-E1 cells in the presence of BMP2. On day 7, cells were assessed by TRAP staining (A) followed by quantification of TRAP + monocytes (MNC) (B) and average osteoclast size (C). Osteoclast function was assessed by osteoclast cultures on bone slice followed by SEM imaging (D). Percentage of resorption area was measured (E). qRT-PCR was performed to evaluate the mRNA expression of *Nfat2* (F), *Trap* (G), *Catk* (H), *Calcr* (I), and *integrin β 3* (J). β -actin was used as an internal control. Data are shown as mean \pm SD. * $P < 0.05$, ** $P < 0.01$.

AR and osteoactivin than in controls, whereas AR and osteoactivin knockdown reduced mineralization in LV-AMPK α 2 cells (Fig. 7F).

We confirmed these results in LV-AMPK α 1 and LV-AMPK α 2 primary osteoblasts (Fig. 7G). A qRT-PCR analysis performed on day 9 showed that the mRNA expression of *Osterix*, *Alp*, *Ibsp*, and *Ocn* was upregulated in response to AR and osteoactivin overexpression in LV-AMPK α 1 cells (Fig. 7H–K). In contrast, AR and osteoactivin knockdown resulted in the downregulation of *Osterix*, *Alp*, *Ibsp* and *Ocn* mRNA expression in LV-AMPK α 2 cells (Fig. 7H–K).

We also confirmed the results described above in LV-AMPK α 1 and LV-AMPK α 2 BMSCs (Fig. 7L). A qRT-PCR analysis performed on day 7 showed that the mRNA expression of *Runx2*, *Alp*, *Ibsp*, and *Ocn* was upregulated in response to AR and osteoactivin overexpression in LV-AMPK α 1 cells (Fig. 7M–P). In contrast, AR knockdown resulted in the downregulation of *Runx2*, *Alp*, and *Ocn* mRNA expression, but had no effect on the level of *Ibsp* in LV-AMPK α 2 cells (Fig. 7M–P). Osteoactivin knockdown also decreased the mRNA expression *Runx2*, *Ibsp* and *Ocn*, but had no effect on the level of *Alp* (Fig. 7M–P).

Adipogenic potential is suppressed by overexpression of the AMPK α 2 subunit. The balance between osteogenesis and adipogenesis in BMSCs is impaired in several human diseases¹⁹, therefore its regulation is of medical importance²⁰. The role of AMPK in adipogenesis was investigated in preadipocyte 3T3-L1 cells stably expressing AMPK α 1 or α 2 subunits. Exogenous AMPK α 1 and α 2 subunits were expressed at high levels in LV-AMPK α 1 and LV-AMPK α 2 3T3-L1 cells (Fig. 8A) respectively, as determined by RT-PCR. The expression of endogenous AMPK α 1 or α 2 was unaffected by the overexpression of the exogenous proteins (Fig. 8A).

LV-AMPK α 1 and LV-AMPK α 2 3T3-L1 cells were then compared in terms of AR expression. *Ar* mRNA level was upregulated in LV-AMPK α 1 and LV-AMPK α 2 cells compared with LV-ctr cells (Fig. 8B). Further, there was upregulation in *Ar* mRNA level in LV-AMPK α 2 compared with LV-AMPK α 1 cells (Fig. 8B). Oil Red O staining (Fig. 8C) and quantification (Fig. 8D) revealed that there were fewer intracellular fat droplets in LV-AMPK α 1 and LV-AMPK α 2 cells than in 3T3-L1 cells. More importantly, the formation of intracellular fat droplets was decreased to a greater degree by overexpressing AMPK α 2 as compared to AMPK α 1 (Fig. 8C,D). A qRT-PCR analysis showed that transcript expression levels of adipogenesis markers including peroxisome proliferator-activated receptor γ (*Ppar γ*), *aP2*, and glucose transporter 4 (*Glut4*) were downregulated




Figure 6. Secretion of proteins involved in bone metabolism from MC3T3-E1 cells expressing AMPK α 1 and α 2. The levels of 36 proteins were measured using a high throughput antibody array and are shown as upregulation (red) or downregulation (blue) in α 2-AMPK vs. α 1-AMPK MC3T3-E1 cells (A). Fluorescent signals (B) and fluorescence intensity (C) corresponding to AR, osteoactivin, M-CSF, RANKL, MMP24 and OPG were measured in MC3T3-E1 cells expressing α 1- and α 2-AMPK. The mRNA expression of AR, osteoactivin, M-CSF, RANKL, MMP24 and OPG in MC3T3-E1 cells expressing α 1- and α 2-AMPK was evaluated by qRT-PCR (D). β -actin was used as an internal control of qRT-PCR. Data are shown as mean \pm SD. * $P < 0.05$, ** $P < 0.01$.

in LV-hAMPK α 1 and LV-hAMPK α 2 as compared to 3T3-L1 cells, with AMPK α 2 having the greater effect (Fig. 8E–G).

AR level is negatively correlated with adipogenesis in BMSCs¹⁸. Given the upregulation in AR expression and inhibition of adipogenesis induced by AMPK α 2 as compared to AMPK α 1 overexpression, a role for AR in adipogenesis was examined by infecting LV-AMPK α 1 and LV-AMPK α 2 3T3-L1 cells with a virus expressing AR and a siRNA against AR respectively, and inducing adipogenic differentiation. On day 15, Oil Red O staining and quantification were used to evaluate adipogenesis and cells were analyzed for *Ppar γ* , *aP2*, and *Glut4* expression by qRT-PCR. AR overexpression suppressed adipogenesis in LV-AMPK α 1 3T3-L1 cells. The inhibition of adipogenesis was rescued in LV-AMPK α 2 3T3-L1 cells by AR knockdown (Fig. 8C–G).

Further, we confirmed the results described above in LV-AMPK α 1 and LV-AMPK α 2 BMSCs. LV-AMPK α 1 and LV-AMPK α 2 BMSCs were infected with a virus expressing AR and a siRNA against AR respectively, and inducing adipogenic differentiation. On day 25, Oil Red O staining and quantification were used to evaluate adipogenesis. AR overexpression suppressed adipogenesis in LV-AMPK α 1 BMSCs. The inhibition of adipogenesis was rescued in LV-AMPK α 2 BMSCs by AR knockdown (Fig. 8H–I).

Role of the AMPK α 2 subunit in the impaired osteogenesis of BMSCs with FD. FD is characterized by an impairment in osteogenic differentiation potential in BMSCs due to activating missense mutations in the guanine nucleotide binding protein α -stimulating (*Gnas*) gene. In normal BMSCs, AMPK α 2 mRNA expression was progressively upregulated during osteogenic differentiation (Fig. 9A). Two *in vitro* models were established that mimicked the pathological features of FD. In the first, BMSCs were generated that expressed a *Gnas* mutant harboring an R201H mutation ($Gs\alpha^{R201H}$); in the second model, BMSCs were treated with an excess of cell membrane-permeable cAMP²¹. Osteogenic differentiation was induced in the cells, and the mRNA expression of AMPK α 2 was assessed on days 0, 2, 4, and 7. LV- $Gs\alpha^{R201H}$ -BMSCs and excess cAMP-treated BMSCs showed the different pattern of AMPK α 2 subunit mRNA expression with normal BMSCs: no statistical difference was observed at day 2 compared with day 0 and there was significant downregulation at day 4 (by 28%) and 7 (by 67%) compared with day 0 in LV- $Gs\alpha^{R201H}$ -BMSCs (Fig. 9B). Accordingly, in excess cAMP-treated BMSC, there was gradual downregulation in AMPK α 2 subunit mRNA expression at day 2 (by 46%), 4 (by 62%) and 7 (by 76%) compared with day 0 (Fig. 9C).




Figure 7. Modulation of osteogenesis in MC3T3-E1, primary osteoblasts and mouse BMSCs expressing $\alpha 1$ and $\alpha 2$ subunits of AMPK via AR and osteoactivin. AR and osteoactivin coding sequences (CDS) were expressed in $\alpha 1$ -AMPK MC3T3-E1 (A), primary osteoblasts (G) and mouse BMSCs (L) and their expression was knocked down in $\alpha 2$ -AMPK MC3T3-E1 (A), primary osteoblasts (G) and mouse BMSCs (L). An empty LV vector (LV-ctr) and a vector expressing scrambled siRNA (LV-scr) served as the respective controls. MC3T3-E1, primary osteoblasts and mouse BMSCs were induced to osteogenic differentiation. On day 7 (MC3T3-E1 and mouse BMSCs) and day 9 (primary osteoblasts) after induction, the expression of the osteogenesis markers *Runx2* (B,M), *Osterix* (H), *Alp* (C,I,N), *Ibsp* (D,J,O), and *Ocn* (E,K,P) was evaluated by qRT-PCR. β -actin was used as an internal control of qRT-PCR. On day 21 after induction, calcium deposition was assessed by alizarin red staining and quantification (F). Data are shown as mean \pm SD; * $P < 0.05$.

To determine whether the downregulation of the AMPK $\alpha 2$ subunit is responsible for the reduced osteogenic differentiation potential in BMSCs treated with excess cAMP, the AMPK $\alpha 2$ subunit was overexpressed by LV transduction in these cells, which were then induced to undergo osteogenic differentiation. Overexpression of the AMPK $\alpha 2$ subunit rescued the impaired osteogenic differentiation in cAMP-treated BMSCs, as evidenced by the increased *ALP*, *IBSP*, and *OCN* transcript levels (Fig. 9D–F), implicating the role of $\alpha 2$ subunit of AMPK in FD pathogenesis.

Discussion

The results of the present study revealed three key functional differences between the AMPK $\alpha 1$ and $\alpha 2$ subunits. The $\alpha 2$ subunit increased osteogenic potential in MC3T3-E1 cells, primary osteoblasts and mouse BMSCs, which involved AR and osteoactivin. Compared to the $\alpha 1$ subunit of AMPK, the $\alpha 2$ subunit inhibited osteoblast-associated induction of osteoclastogenesis in MC3T3-E1 cells via downregulation of M-CSF and RANKL. Finally, compared to $\alpha 1$, overexpression of the $\alpha 2$ subunit suppressed adipogenesis in 3T3-L1 cells, which also involved AR.

Mammalian AMPK has two isoforms of the α and β and three of the γ subunit, and the various isoforms of each subunit have distinct biological functions^{22,23}. A769622 activates AMPK both allosterically and by inhibiting the dephosphorylation of AMPK α^{Thr172} by specific phosphatases²⁴. Its mode of action does not involve binding to the γ subunit, unlike other AMPK activators such as AMP and AICAR, but instead depends on the presence of the β subunit²⁵. Interestingly, it was shown that A769622 is selective for the $\beta 1$ isoform and does not activate AMPK heterotrimers containing $\beta 2$ subunits²⁶. In contrast, only AMPK $\beta 2$ can be modified posttranslationally by PIASy-dependent SUMOylation, leading to activation of the AMPK complex²⁵. One study screened 12,000 genes in the H1299 human lung carcinoma line and found 133 genes that were either induced or repressed in response to p53-dependent cell growth arrest and apoptotic conditions, including $\beta 1$ but no other AMPK subunits²⁷. Another study demonstrated that $\alpha 1$ and $\gamma 1$ are almost exclusively localized in the cytoskeleton, while $\alpha 2$ and $\gamma 2$




Figure 8. Adipogenesis in 3T3-L1 and mouse BMSCs expressing AMPK α 1 and α 2 subunits. LV vectors expressing AMPK α 1 and α 2 subunits were used to infect 3T3-L1 cells, and positive clones were selected with puromycin. An empty LV vector served a control (LV-ctr). The expression of exogenous and endogenous AMPK α 1 and α 2 was evaluated by RT-PCR (A). AR mRNA expression level was evaluated by qRT-PCR (B). β -actin was used an internal control. Adipogenesis was induced in infected cells in which AR was overexpressed (LV-AR) or knocked down (LV-siAR), and Oil Red O staining (C) and quantification (D) was used to assess the presence of fat droplets. The mRNA expression of the adipogenesis markers *Ppar γ* (E), *ap2* (F), and *Glut4* (G) was evaluated by qRT-PCR. Adipogenesis was induced in mouse BMSCs overexpressing AMPK α 1 and α 2 in which AR was overexpressed (LV-AR) or knocked down (LV-siAR), and Oil Red O staining (H) and quantification (I) was used to assess the presence of fat droplets. Data are shown as mean \pm SD. * $P < 0.05$.

are present in all subcellular fractions, including the nucleus²⁸. These data suggest that pharmacological interventions targeted to specific AMPK subunit isoforms can selectively modify particular AMPK functions.

The α subunit of AMPK is the main catalytic domain of the AMPK complex. A dominant-negative α 2 subunit attenuated the mutant AMPK γ 2 phenotype, and AMPK complexes containing α 2 rather than α 1 subunit mediate the effects of AMPK γ 2 mutations²². AMPK α 2 is the main effector of basal and AICAR-stimulated AMPK activity, including AICAR-induced glucose uptake²⁹. Clot retraction was impaired in platelets from AMPK α 2^{-/-} but not AMPK α 1^{-/-} mice²³, and AMPK α 2 knockout mice showed increased sensitivity to diet-induced obesity and insulin resistance, whereas no metabolic defects were observed in α 1 knockout mice.

Few reports have compared the functions of AMPK α 1 and α 2 subunits. The AMPK agonists AICAR and metformin induce osteogenesis in MC3T3-E1 cells^{30–34}, and metformin causes increases in ALP activity, collagen synthesis, OC production, and extracellular Ca²⁺ deposition *in vitro*, possibly by increasing *Runx2* expression. When primary osteoblasts were co-treated with AICAR and the AMPK antagonist compound C, the latter suppressed the stimulatory effect of the agonist on bone nodule formation. The present study analyzed differences in the osteogenic potential of MC3T3-E1 cells expressing the α 1 or α 2 subunits of AMPK. The findings that the α 2 subunit conferred the cells with greater osteogenic potential as compared to α 1 are at variance with those of another study, which found no differences in tibial bone mass between AMPK α 2 knockout and wild-type mice, although both cortical and trabecular bone compartments were smaller in the mutants³⁵. In addition to possible differences attributable to the model systems that were used (*in vivo* vs. *in vitro* in this study), one possible reason for the discrepancy between the findings is the low expression of α 2 relative to the α 1 isoform in the skeletal system.

α 1 is the predominant AMPK isoform expressed (albeit at low levels) in BMSCs, preosteoblasts, and preadipocytes^{8,35,36}. The antibody array data presented here showed that the levels of many markers of bone metabolism differed between MC3T3-E1 cells expressing α 1 or α 2 subunits, including AR, basic fibroblast growth factor, interleukin-6 and -17, MCP-1, M-CSF, macrophage inflammatory protein 1a, MMP9, osteoactivin, tumor necrosis factor α , RANKL, and MMP24 (Supplementary Fig. 1). Of these, osteoactivin and especially AR were implicated in the differences in osteogenesis potential between α 1 and α 2. This is consistent with studies showing that AR deficiency leads to tissue-nonspecific ALP downregulation followed by decreased phosphate production, ultimately reducing bone mineralization. Similar results were observed in osteoblast-specific AR knockout mice, in which AR was found to stimulate osteoblast differentiation and suppress bone resorption^{37,38}; AR mutants developed osteoporosis and showed decreased BMSC osteogenesis resulting from the downregulation of *Runx2*³⁹.




Figure 9. Role of AMPK $\alpha 2$ in the fibrous dysplasia (FD) phenotype. Two *in vitro* cell models were established that mimic the pathological features of FD: in one model, human BMSCs stably expressed a mutant GNAS protein harboring an R201H mutation ($G\alpha^{R201H}$); in the second model, human BMSCs were treated with an excess of membrane-permeable cAMP. Osteogenic differentiation was induced in the cells. On days 0, 2, 4, and 7, the expression of the AMPK $\alpha 2$ subunit was evaluated by qRT-PCR (A–C). Results are expressed as fold change in mRNA abundance relative to day 0 cultures. AMPK $\alpha 2$ subunit was overexpressed in cells with and without cAMP treatment. These cells were induced to osteogenesis. The mRNA expression of ALP (D), IBSP (E), and OCN (F) was evaluated by qRT-PCR. Data are shown as mean \pm SD. * $P < 0.05$, ** $P < 0.01$.

In addition, an enhancement of osteogenesis, AR also suppresses adipogenesis. Androgen treatment inhibits adipocyte differentiation and body fat formation *in vitro* and in rodent and nonhuman primate models, as well as rosiglitazone-induced adipogenesis in human BMSCs; it also promotes interactions between β -catenin, AR, and T-cell factor 4 to suppress adipogenic differentiation of 3T3-L1 cells⁴⁰, which were induced to undergo adipogenesis by overexpression of the $\alpha 1$ and $\alpha 2$ subunits of AMPK in this study. The weaker induction in $\alpha 2$ -AMPK 3T3-L1 corresponded to a greater upregulation in AR expression as compared to the adipogenic induction and AR level in $\alpha 1$ -AMPK 3T3-L1 cells. Adipogenesis was rescued in $\alpha 2$ -AMPK 3T3-L1 and inhibited in $\alpha 1$ -AMPK 3T3-L1 cells upon AR knockdown and overexpression, respectively, suggesting that the functional differences between $\alpha 1$ and $\alpha 2$ involve AR signaling.

Osteoclast differentiation and maturation depend on cues from the microenvironment, especially from osteoblasts through cell-cell contact and paracrine signaling. This study provides evidence that osteoblast-associated osteoclastogenesis was reduced in bone marrow monocytes co-cultured with MC3T3-E1 cells expressing $\alpha 2$ as compared to $\alpha 1$ and likely involves RANKL and M-CSF, as the expression of these two proteins was downregulated in the former. AR, which was upregulated in AMPK $\alpha 2$ - relative to $\alpha 1$ -expressing MC3T3-E1, may also be involved, since it inhibits bone resorption⁴¹ and AR-deficient mice exhibit a calvarial and femoral bone loss phenotype.

The most intriguing finding of the present study as that AMPK $\alpha 2$ expression was impaired during osteogenesis in an FD model. In normal BMSCs, $\alpha 2$ subunit transcript level gradually increased during osteogenic differentiation; however, this was abrogated and even reversed in BMSCs exhibiting the FD phenotype, and the defect in osteogenesis in these cells was rescued by overexpression of AMPK $\alpha 2$, suggesting that the $\alpha 2$ subunit may be a critical factor in the pathogenesis of FD. For instance, $\alpha 2$ may be involved in the overactivation of bone resorption as our findings demonstrate a negative relationship between $\alpha 2$ expression and osteoclastogenesis.

In conclusion, the results from this study indicate that the $\alpha 2$ and $\alpha 1$ subunits of AMPK have several functional differences, with $\alpha 2$ conferring stronger osteogenic potential and a weaker ability to induce osteoblast-associated osteoclastogenesis in MC3T3-E1 cells as well as conferring a lower adipogenic potential to 3T3-L1 cells. These findings provide a basis for developing drugs that can differentially target the $\alpha 1$ and $\alpha 2$ subunits of AMPK to treat diseases such as obesity and osteoporosis that are associated with mutations in specific AMPK subunits.

Materials and Methods

Cell cultures. *MC3T3-E1 cells.* MC3T3-E1 cells were cultured in α -minimal essential medium (α -MEM) (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and

100 mg/ml streptomycin (all from Hyclone, Logan, UT, USA). In all experiments, cells were cultured in a humidified atmosphere at 37 °C and 5% CO₂ with the medium changed every 3 days.

MC3T3-E1 cells were treated with recombinant human bone morphogenetic protein (BMP)2 (R&D, Minneapolis, MN, USA) at a final concentration of 100 ng/ml to induce osteogenesis.

Primary calvarial osteoblasts. Four-day-old male C57BL/6J mice were killed with a lethal dose of sodium pentobarbital. Calvaria was dissected, cleaned of soft tissue, and maintained in PBS buffer. The cleaned calvaria was cut into small pieces of 1–2 mm² and washed with PBS. The bone pieces were incubated with 2 mg/ml collagenase II (Sigma, St. Louis, MO) solution for 2 h at 37 °C in a shaking water bath. Then, the fragments were washed with α -MEM supplemented with 10% FBS and cultured in culture medium (α -MEM containing 10% FBS, 100 U/ml penicillin, 100 μ g/ml streptomycin). The culture flasks were stored in a humidified atmosphere of 5% CO₂ in air at 37 °C. After confluence, the bone fragments were removed and the confluent layers were trypsinized and the cells were replated.

Primary calvarial osteoblasts were induced to osteogenesis by Osteogenesis Induction Medium (OIM) containing 10 mM β -glycerophosphate and 100 μ g/ml ascorbic acid.

BMSCs. Mouse BMSCs were purchased from Cyagen Bioscience Inc. Human BMSCs were isolated and expanded using a modified version of a previously described method^{42,43}. The donor was healthy and had no metabolic or other diseases or inherited conditions that could affect the current study. Written informed consent was obtained from the donor, and the study was approved by the Ethics Committee of Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medicine. Methods used in this study were carried out in accordance with the the relevant guidelines and regulations.

Mouse BMSCs were induced to osteogenesis by Osteogenesis Induction Medium (OIM) containing 10 mM β -glycerophosphate, 100 μ g/ml ascorbic acid, and 10 nM dexamethasone. To investigate the effect of excess cAMP on AMPK α 1 and α 2 expression in human BMSCs, confluent cells were exposed to medium containing BMP2 and 2 mM dibutyryl-cAMP (Sigma, St. Louis, MO, USA).

3T3-L1 cells. 3T3-L1 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco) supplemented with 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin. Adipogenic differentiation of 3T3-L1 and mouse BMSCs was induced as previously described²⁰. Briefly, confluent cells were treated with a complete adipogenic hormone cocktail consisting of DMEM supplemented with 10% FBS, 10 g/ml insulin, 0.5 mM methylisobutylxanthine, and 1 μ M dexamethasone (all from Sigma). The day differentiation was induced was considered as day 0. On day 3, the culture medium was replaced with DMEM containing only insulin and 10% FBS. On day 6, the complete adipogenic hormone cocktail was again added.

Osteoblast-associated osteoclastogenesis. Bone marrow monocytes isolated from long bones of 6-week-old C57BL/6 mice were cultured with MC3T3-E1 in the presence of BMP2 (100 ng/ml) for 7 days. The cells were then fixed and stained for TRAP. TRAP-positive multinuclear cells (>3 nuclei/cell) were considered as osteoclasts and were counted. The total area of TRAP-positive regions were quantified using Image J software (National Institutes of Health, Bethesda, MD, USA) in each sample in 5 randomly selected fields of view.

Bone absorption assay. Bone marrow monocytes were cultured with MC3T3-E1 in the presence of BMP2 (100 ng/ml) for 7 days on bovine bone slices. Cells on bone slices were then removed by mechanical agitation and sonication. Bone resorption pits were visualized under a scanning electron microscope (SEM) (FEI Quanta 250), and the percentage of bone resorption area was quantified using Image J software.

Reverse transcription (RT)- and real-time PCR. Total cellular RNA was isolated from cultured cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Primers used in all reactions are shown in Supplementary Table 1. For RT-PCR, single-stranded cDNA was reverse-transcribed from 1 μ g total RNA using reverse transcriptase with an oligo-dT primer. PCR was carried out with 1 μ l cDNA using the following cycling parameters: 30 cycles of 94 °C for 40 s, 60 °C for 40 s, and 72 °C for 40 s. PCR products were analyzed by agarose gel electrophoresis. Real-time PCR was carried out on a 96-well plate ABI Prism 7500 Sequence Detection system (Applied Biosystems, Foster City, CA, USA) using SYBR Green PCR Master Mix (Takara Bio Inc., Otsu, Japan). Cycling conditions were as follows: 40 cycles of 94 °C for 5 s, 60 °C for 34 s, and 72 °C for 30 s. The comparative 2^{- $\Delta\Delta$ Ct} method was used to calculate the relative expression of each target gene as previously described⁴²; the expression levels of all genes were normalized to that of β -actin.

Lentiviral transduction. LV vectors containing the coding sequences of human AMPK α 1 and α 2 subunits, AR, and osteoactivin and short interfering (si)RNAs against AR and osteoactivin were purchased from Genecopoeia (Rockville, MD, USA). LV particles were generated as previously described²¹. Briefly, 1.3–1.5 \times 10⁶ 293T cells were plated in a 10-cm dish and the transfection complex was added directly to the culture medium when cells reached 70–80% confluence. After incubation in a CO₂ incubator at 37 °C, LV particle-containing medium was collected 48 h post-transfection.

Bone metabolism markers array. Semi-quantitative sandwich-based bone metabolism markers arrays (Human Cytokine Array L-Series; RayBiotech, Atlanta, GA, USA) were used to detect 36 markers of bone metabolism on a glass slide matrix. Biotin-conjugated antibodies used for detection were combined as a single cocktail for later use. Printed slides were placed in chambers to allow incubation of each array with a different sample. Arrays were incubated in blocking buffer followed by whole cell lysis samples. After extensive washing to remove

non-specific binding, the antibody cocktail was added to the arrays. After additional washes, the arrays were incubated with the streptavidin-conjugated HiLyte Fluor 532 (Anaspec, Fremont, CA), and the fluorescent signal was visualized using a GenePix 4200A laser-based scanner system (Molecular Dynamics, Sunnyvale, CA) on the green channel. Two replicates were spotted for each antibody, and the average median signal intensity for both spots (with the local background subtracted) was used to calculate protein level.

Oil Red O staining and quantification. Cultured cells were stained with Oil Red O as previously described¹⁹ to evaluate adipogenesis. Briefly, cells were washed twice with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde for 2 h at 4 °C. After two washes in PBS, cells were stained for 2 h in freshly diluted Oil Red O solution consisting of six parts Oil Red O stock solution (0.5% in isopropanol) and four parts water at 4 °C. The stain was removed from the cells with two PBS washes and cells were examined with an inverted microscope. To measure the quantification of lipid accumulation, Oil red O was eluted by adding 100% isopropanol and optical density was detected using a spectrophotometer at 520 nm.

Alizarin Red staining and quantification. Osteogenesis was examined by staining mineralized nodules with Alizarin Red S. After fixation, cells were washed with PBS and soaked in 40 mM Alizarin Red (pH 4.2) for 30 min at 37 °C, then washed with PBS and imaged. Decalcification was performed using 0.1 M HCl overnight at 4 °C. Then, 20 µL of samples were transferred to the test tubes containing 1 mL of methyl thymol blue solution and 1 mL of alkaline solution. Absorbance was determined at 610 nm.

Ectopic Bone Formation. All animal procedures were approved by the Animal Ethics Committee of Shanghai Ninth People's Hospital Affiliated to Shanghai JiaoTong University School of Medicine and were performed in strict accordance with the NIH guidelines for the care and use of laboratory animals (NIH Publication No. 85e23 Rev. 1985). There were 4 groups in the experiment, (1) β -tricalcium phosphate (β -TCP) alone (Vehicle), (2) β -TCP loading LV-ctr MC3T3-E1 cells (LV-ctr), (3) β -TCP loading LV-AMPK α 1 MC3T3-E1 cells (LV-AMPK α 1) and (4) β -TCP loading LV-AMPK α 2 MC3T3-E1 cells (LV-AMPK α 2). A modified version of a previously described method was used^{44,45}. All MC3T3-E1 cells were treated with rhBMP-2 at a final concentration of 100 ng/ml to induce osteogenesis for 3 days. Then approximately 2.0×10^6 cells were seeded on each β -TCP disk (φ 6 mm \times H 2 mm, Bio-lu Biomaterials Company, Shanghai, China). After 12 hours, the cell-scaffold complex was implanted into the intramuscular pocket of the femur of 8-week-old nude mice (BALB/c, nu/nu; SIPPR-BK Laboratory Animal Co. Ltd, Shanghai, China). Eight weeks after implantation, samples were harvested, fixed in 4% paraformaldehyde for micro-CT. Then these complexes were decalcified, and embedded in paraffin. Thin sections (5 µm) were stained with hematoxylin and eosin (H&E).

Statistical analysis. Mean differences were evaluated by the Student's t test for two-sample comparisons and one-way analysis of variance (ANOVA) for multiple comparisons using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Tukey's test was used to identify significant differences in ANOVA. Data from at least three independent experiments were analyzed and are presented as the mean \pm SD. $P < 0.05$ was defined as statistically significant.

References

- Kang, H., Viollet, B. & Wu, D. Genetic deletion of catalytic subunits of AMP-activated protein kinase increases osteoclasts and reduces bone mass in young adult mice. *J Biol Chem* **288**, 12187–12196 (2013).
- Hardie, D. G., Hawley, S. A. & Scott, J. W. AMP-activated protein kinase—development of the energy sensor concept. *The Journal of physiology* **574**, 7–15 (2006).
- Lage, R., Dieguez, C., Vidal-Puig, A. & Lopez, M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. *Trends in molecular medicine* **14**, 539–549 (2008).
- Karsenty, G. & Ferron, M. The contribution of bone to whole-organism physiology. *Nature* **481**, 314–320 (2012).
- Ducy, P. *et al.* Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. *Cell* **100**, 197–207 (2000).
- Kasai, T. *et al.* Osteoblast differentiation is functionally associated with decreased AMP kinase activity. *J Cell Physiol* **221**, 740–749 (2009).
- Molinuevo, M. S. *et al.* Effect of metformin on bone marrow progenitor cell differentiation: *in vivo* and *in vitro* studies. *Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research* **25**, 211–221 (2010).
- Quinn, J. M. *et al.* Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* **24**, 275–285 (2010).
- Gao, G. *et al.* Non-catalytic beta- and gamma-subunit isoforms of the 5'-AMP-activated protein kinase. *J Biol Chem* **271**, 8675–8681 (1996).
- Woods, A. *et al.* Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex *in vitro*. *J Biol Chem* **271**, 10282–10290 (1996).
- Carling, D. *et al.* Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism. *J Biol Chem* **269**, 11442–11448 (1994).
- Stapleton, D. *et al.* Mammalian AMP-activated protein kinase subfamily. *J Biol Chem* **271**, 611–614 (1996).
- Vavvas, D. *et al.* Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle. *J Biol Chem* **272**, 13255–13261 (1997).
- Matsuo, K. & Irie, N. Osteoclast-osteoblast communication. *Archives of biochemistry and biophysics* **473**, 201–209 (2008).
- Abdelmagid, S. M. *et al.* Mutation in osteonectin decreases bone formation *in vivo* and osteoblast differentiation *in vitro*. *The American journal of pathology* **184**, 697–713 (2014).
- Moussa, F. M. *et al.* Osteonectin promotes osteoblast adhesion through HSPG and α 5 β 1 integrin. *Journal of cellular biochemistry* **115**, 1243–1253 (2014).
- Hartig, S. M. *et al.* Androgen receptor agonism promotes an osteogenic gene program in preadipocytes. *Biochemical and biophysical research communications* **434**, 357–362 (2013).

18. Huang, C. K. *et al.* Loss of androgen receptor promotes adipogenesis but suppresses osteogenesis in bone marrow stromal cells. *Stem cell research* **11**, 938–950 (2013).
19. Zhao, Q. H. *et al.* PPAR γ forms a bridge between DNA methylation and histone acetylation at the C/EBP α gene promoter to regulate the balance between osteogenesis and adipogenesis of bone marrow stromal cells. *The FEBS journal* **280**, 5801–5814 (2013).
20. Fan, Q., Tang, T., Zhang, X. & Dai, K. The role of CCAAT/enhancer binding protein (C/EBP)- α in osteogenesis of C3H10T1/2 cells induced by BMP-2. *J Cell Mol Med* **13**, 2489–2505 (2009).
21. Fan, Q. M. *et al.* The CREB-Smad6-Runx2 axis contributes to the impaired osteogenesis potential of bone marrow stromal cells in fibrous dysplasia of bone. *J Pathol* **228**, 45–55 (2012).
22. Ahmad, F. *et al.* Increased α 2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. *Circulation* **112**, 3140–3148 (2005).
23. Randriamboavonjy, V. *et al.* AMPK α 2 subunit is involved in platelet signaling, clot retraction, and thrombus stability. *Blood* **116**, 2134–2140 (2010).
24. Cool, B. *et al.* Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. *Cell metabolism* **3**, 403–416 (2006).
25. Sanz, P., Rubio, T. & Garcia-Gimeno, M. A. AMPK β subunits: more than just a scaffold in the formation of AMPK complex. *The FEBS journal* **280**, 3723–3733 (2013).
26. Scott, J. W. *et al.* Thienopyridone drugs are selective activators of AMP-activated protein kinase β 1-containing complexes. *Chemistry & biology* **15**, 1220–1230 (2008).
27. Li, J., Jiang, P., Robinson, M., Lawrence, T. S. & Sun, Y. AMPK- β 1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. *Carcinogenesis* **24**, 827–834 (2003).
28. Pinter, K., Jefferson, A., Czibik, G., Watkins, H. & Redwood, C. Subunit composition of AMPK trimers present in the cytokinetic apparatus: Implications for drug target identification. *Cell Cycle* **11**, 917–921 (2012).
29. Jorgensen, S. B. *et al.* Knockout of the α 2 but not α 1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1- β -D-ribofuranoside but not contraction-induced glucose uptake in skeletal muscle. *J Biol Chem* **279**, 1070–1079 (2004).
30. Cortizo, A. M., Sedlinsky, C., McCarthy, A. D., Blanco, A. & Schurman, L. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. *European journal of pharmacology* **536**, 38–46 (2006).
31. Kanazawa, I. *et al.* Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. *BMC cell biology* **8**, 51 (2007).
32. Kanazawa, I., Yamaguchi, T., Yano, S., Yamauchi, M. & Sugimoto, T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. *Biochemical and biophysical research communications* **375**, 414–419 (2008).
33. Kanazawa, I., Yamaguchi, T., Yano, S., Yamauchi, M. & Sugimoto, T. Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. *American journal of physiology. Endocrinology and metabolism* **296**, E139–E146 (2009).
34. Jang, W. G. *et al.* Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. *Bone* **48**, 885–893 (2011).
35. Shah, M. *et al.* AMP-activated protein kinase (AMPK) activation regulates *in vitro* bone formation and bone mass. *Bone* **47**, 309–319 (2010).
36. Wang, Y., Fan, Q., Ma, R., Lin, W. & Tang, T. Gene expression profiles and phosphorylation patterns of AMP-activated protein kinase subunits in various mesenchymal cell types. *Chinese medical journal* **127**, 2451–2457 (2014).
37. Chiang, C. *et al.* Mineralization and bone resorption are regulated by the androgen receptor in male mice. *Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research* **24**, 621–631 (2009).
38. Notini, A. J. *et al.* Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. *Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research* **22**, 347–356 (2007).
39. Tsai, M. Y. *et al.* The reduced trabecular bone mass of adult ARKO male mice results from the decreased osteogenic differentiation of bone marrow stroma cells. *Biochemical and biophysical research communications* **411**, 477–482 (2011).
40. Singh, R. *et al.* Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with β -catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. *Endocrinology* **147**, 141–154 (2006).
41. Kawano, H. *et al.* Suppressive function of androgen receptor in bone resorption. *Proc Natl Acad Sci USA* **100**, 9416–9421 (2003).
42. Bian, Z. Y., Fan, Q. M., Li, G., Xu, W. T. & Tang, T. T. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. *Cancer Sci* **101**, 2554–2560 (2010).
43. Xu, W. T., Bian, Z. Y., Fan, Q. M., Li, G. & Tang, T. T. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. *Cancer Lett* **281**, 32–41 (2009).
44. Wang, Y. G. *et al.* AMPK promotes osteogenesis and inhibits adipogenesis through AMPK-G β 1-OPN axis. *Cell Signal* **28**, 1270–1282 (2016).
45. Scott, M. A. *et al.* Brief review of models of ectopic bone formation. *Stem Cells and Development*. **21**(5), 655–667, doi: 10.1089/scd.2011.0517 (March 2012).

Acknowledgements

This study was supported by a grant from the National Natural Science Foundation of China (81672205, 81000778, 81370050 and 81172549), and the Doctoral Innovation Foundation from Shanghai Jiaotong University School of Medicine (BXJ201330).

Author Contributions

T.-t.T., Q.-m.F. and K.-r.D. conceived and designed the research; Y.-g.W., Q.-m.F., X.-g.H. and Y.Y. performed the experiments; Y.-g.W., Q.-m.F. and H.Q. analyzed the data. T.-t.T., Q.-m.F., K.-r.D. and Y.-g.W. wrote and revised the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Wang, Y.-g. *et al.* Functional differences between AMPK α 1 and α 2 subunits in osteogenesis, osteoblast-associated induction of osteoclastogenesis, and adipogenesis. *Sci. Rep.* **6**, 32771; doi: 10.1038/srep32771 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016